Application Registration Study of ILE in Patients With Acute Poisoning
ILE
1 other identifier
observational
500
0 countries
N/A
Brief Summary
In this study, the investigators aimed to study the effect of ILE in the treatment of acute fat-soluble substance poisoning,to further clarify the relevant mechanism of ILE in the treatment of fat-soluble drug poisoning,to standardize the relevant procedures of ILE detoxification treatment and further explore the adverse reactions and coping strategies of ILE treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 1, 2021
CompletedStudy Start
First participant enrolled
November 30, 2021
CompletedFirst Posted
Study publicly available on registry
December 8, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedDecember 8, 2021
September 1, 2021
1 month
November 1, 2021
December 2, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
mortality rate
Patient mortality within 24 hours
24 hours
Secondary Outcomes (2)
Circulatory system
24 hours
mortality rate
1 week and 28 days
Eligibility Criteria
According to the indications of ILE in the treatment of poisoning in clinical toxicology, the research objects are divided into the following categories: 1. Calcium channel blocker poisoning 2. Beta blocker drug poisoning 3. Tricyclic antidepressant poisoning 4. Organophosphorus (fat-soluble) pesticide poisoning, such as: chlorpyrifos, profenofos, diazinon, fenthion, phosphaphos, quinalphos, butylpyrimidin, thiazophos, omethoate, dimethoate Methionine, triazophos, thiomethionine, ethion, sulfoxiphos, imiphos, fosfoxcarb, pyrifoxaphos, hydrocarbophos, phorate, methyl parathion, parasulfur Phosphorus, dichlorvos, pyridoxine, etc. 5. Local anesthetic poisoning 6. Poisoning by other fat-soluble substances
You may qualify if:
- Diagnosed as acute fat-soluble drug and organophosphorus (fat-soluble) pesticide poisoning;
- Conventional treatment is ineffective, especially for patients with circulatory failure, such as ventricular arrhythmia, shock, cardiac arrest, etc., who need intravenous fat emulsion treatment;
- Those who are not allergic to fat milk;
- Sign informed consent.
You may not qualify if:
- Mergers with insufficiency of important organs;
- Patients with malignant tumors;
- Severe mental disorder affects the treatment;
- Those with incomplete clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking Union Medical College Hospitallead
- The Affiliated Hospital of Qingdao Universitycollaborator
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicinecollaborator
- People's Hospital of Deyang Citycollaborator
- Binzhou Medical Universitycollaborator
- People's Hospital of Zhengzhou Universitycollaborator
Biospecimen
Take the patient's blood for general laboratory tests
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Month
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 1, 2021
First Posted
December 8, 2021
Study Start
November 30, 2021
Primary Completion
December 30, 2021
Study Completion
October 1, 2025
Last Updated
December 8, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share